Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP7 | P09237 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9721480 | 1.00 | CHRM1 (0.47) | CHRM1DDB1CRBNHTTNAMPT | |
| SCHEMBL9721473 | 1.00 | CHRM1 (0.47) | CHRM1DDB1CRBNHTTNAMPT | |
| SCHEMBL9721501 | 1.00 | CHRM1 (0.47) | CHRM1DDB1CRBNHTTNAMPT | |
| SCHEMBL9721512 | 1.00 | CHRM1 (0.47) | CHRM1DDB1CRBNHTTNAMPT | |
| SCHEMBL11337013 | 0.87 | HSD17B10 (0.44) | DDB1CRBNHTTNPC1RAB9A | |
| SCHEMBL11337008 | 0.87 | HSD17B10 (0.44) | DDB1CRBNHTTNPC1RAB9A | |
| SCHEMBL11337006 | 0.87 | HSD17B10 (0.44) | DDB1CRBNHTTNPC1RAB9A | |
| SCHEMBL18283911 | 0.84 | HDAC1 (0.48) | — | |
| SCHEMBL5241830 | 0.82 | EPHX2 (0.51) | NPC1RAB9A | |
| SCHEMBL7348189 | 0.81 | NPSR1 (0.58) | CHRM1HTTNAMPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050095200-A1 | Prokinetic drugs assistance to small intestine imaging | SCHWARZBERG MOSHE (IL) | 2005-05-05 | — | — | US | claimed |
| EP-3026049-B1 | METHOD FOR PREPARING BENZAMIDE DERIVATIVE, NOVEL INTERMEDIATE USED IN PREPARATION OF BENZAMIDE, AND METHOD FOR PREPARING NOVEL INTERMEDIATE | DONG A ST CO LTD (KR) | 2021-09-22 | — | — | EP | disclosed |
| US-9771348-B2 | Method for preparing benzamide derivative, novel intermediate used in preparation of benzamide, and method for preparing novel intermediate | DONG-A ST CO., LTD (KR) | 2017-09-26 | — | — | US | disclosed |
| US-20160185751-A1 | METHOD FOR PREPARING BENZAMIDE DERIVATIVE, NOVEL INTERMEDIATE USED IN PREPARATION OF BENZAMIDE, AND METHOD FOR PREPARING NOVEL INTERMEDIATE | DONG-A ST CO., LTD (KR) | 2016-06-30 | — | — | US | disclosed |
| EP-2560955-B1 | NOVEL BENZAMIDE DERIVATIVES | DONG A PHARM CO LTD (KR) | 2016-06-29 | — | — | EP | disclosed |
| EP-3026049-A1 | METHOD FOR PREPARING BENZAMIDE DERIVATIVE, NOVEL INTERMEDIATE USED IN PREPARATION OF BENZAMIDE, AND METHOD FOR PREPARING NOVEL INTERMEDIATE | Dong-A ST Co., Ltd. (KR) | 2016-06-01 | — | — | EP | disclosed |
| US-9221790-B2 | Benzamide derivatives | DONG-A PHARM. CO., LTD. (KR) | 2015-12-29 | — | — | US | disclosed |
| US-20130085160-A1 | NOVEL BENZAMIDE DERIVATIVES | DONG-A PHARM. CO., LTD. (KR) | 2013-04-04 | — | — | US | disclosed |
| EP-2560955-A2 | NOVEL BENZAMIDE DERIVATIVES | Dong-A Pharm.Co., Ltd. (KR) | 2013-02-27 | — | — | EP | disclosed |
| US-8318742-B2 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-11-27 | — | — | US | disclosed |
| US-4962115-A | Stimulate motility of gastrointestinal system | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-10-09 | — | — | US | disclosed |
| EP-0389037-A1 | N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-09-26 | — | — | EP | disclosed |
| US-4906643-A | Substituted N-(3-hydroxy-4-piperidinyl)benzamides as gastrointestinal agents | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-03-06 | — | — | US | disclosed |
| US-4906643-A | Substituted N-(3-hydroxy-4-piperidinyl)benzamides as gastrointestinal agents | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-03-06 | — | — | US | disclosed |
| EP-0299566-A2 | Novel substituted N-(3-hydroxy-4-piperidinyl)benzamides | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-01-18 | — | — | EP | disclosed |
| EP-0299566-A2 | Novel substituted N-(3-hydroxy-4-piperidinyl)benzamides | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-01-18 | — | — | EP | disclosed |
| EP-0076530-B1 | NOVEL N-(3-HYDROXY-4-PIPERIDINYL)BENZAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-12-11 | — | — | EP | disclosed |
| EP-0076530-B1 | NOVEL N-(3-HYDROXY-4-PIPERIDINYL)BENZAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-12-11 | — | — | EP | disclosed |
| EP-0076530-A2 | Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-04-13 | — | — | EP | disclosed |
| EP-0076530-A2 | Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185751-A1 | METHOD FOR PREPARING BENZAMIDE DERIVATIVE, NOVEL INTERMEDIATE USED IN PREPARATION OF BENZAMIDE, AND METHOD FOR PREPARING NOVEL INTERMEDIATE | HTR4, HTR5A, HTR2B | CHRM1 1010/4885DDB1 4831/4885CRBN 3588/4885 |
| US-20130085160-A1 | NOVEL BENZAMIDE DERIVATIVES | HTR4, GPR4, HTR5A | CHRM1 714/4885DDB1 4800/4885CRBN 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.